Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
Completed · Phase 1/Phase 2
Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of topotecan plus sargramostim in treating patients who have advanced cancer.
Key facts
- Study ID
- NCT00002950
- Run by
- Yale University
- People needed
- 25
- Starts
- 1996-09-26
- Expected to finish
- 2002-02-10
- Last updated by the study team
- 2020-08-17
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale Comprehensive Cancer Center — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.